Patents by Inventor Thomas Langer

Thomas Langer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11189806
    Abstract: The present invention relates to heteroleptic complexes comprising a phenylimidazole or phenyltriazole unit bonded via a carbene bond to a central metal atom, and phenylimidazole ligands attached via a nitrogen-metal bond to the central atom, to OLEDs which comprise such heteroleptic complexes, to light-emitting layers comprising at least one such heteroleptic complex, to a device selected from the group consisting of illuminating elements, stationary visual display units and mobile visual display units comprising such an OLED, to the use of such a heteroleptic complex in OLEDs, for example as emitter, matrix material, charge transport material and/or charge blocker.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: November 30, 2021
    Assignee: UDC Ireland Limited
    Inventors: Evelyn Fuchs, Oliver Molt, Korinna Dormann, Thomas Gessner, Nicolle Langer, Ingo Muenster, JianQiang Qu, Christian Lennartz, Christian Schildknecht, Soichi Watanabe, Gerhard Wagenblast, Guenter Schmid, Herbert Friedrich Boerner, Volker van Elsbergen
  • Publication number: 20210367964
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Publication number: 20210313996
    Abstract: Oscillator circuitry is disclosed. The oscillator circuitry comprises a free-running oscillator for generating pulses at a frequency, and a frequency adjustment circuit for adaptively adjusting the frequency of the free-running oscillator. The frequency adjustment circuit comprises a counter configured to count a number of pulses generated by the free-running oscillator and logic configured to compare the number of pulses with an expected number of pulses (corresponding to a target frequency) to determine a difference value and to adjust the frequency of the free-running oscillator in dependence on the difference value. The frequency adjustment circuit is configured, in response to receiving a synchronisation pulse, to trigger an update of the number of pulses to be compared.
    Type: Application
    Filed: August 19, 2019
    Publication date: October 7, 2021
    Inventors: Volker LANGER, Thomas KATTWINKEL
  • Patent number: 11102729
    Abstract: A data transmission system may comprise a first transmission chain comprising a first transmission power controller, the first transmission power controller being configured to operate in an open loop power control mode or in a closed loop power control mode; a second transmission chain; and a power control mode selector configured to select the first transmission power controller to operate in the open loop power control mode or in the closed loop power control mode based on at least one quantity indicative of interference induced by the second transmission chain in the first transmission power controller when operating in the closed loop power control mode.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 24, 2021
    Assignee: Apple Inc.
    Inventors: Andreas Langer, Thomas Bruder
  • Patent number: 11097858
    Abstract: Embodiments described herein include a satellite cover panel for covering a satellite, particularly a payload bay of a satellite comprising an energy storage module, at least one energy generating module defining, at least partially, a first outer surface of the satellite cover panel, and a logic board defining, at least partially, a second outer surface of the satellite cover panel, wherein the first outer surface and the second outer surface face away from each other and from the energy storage module.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 24, 2021
    Assignee: Technische Universität München
    Inventors: Thomas Grübler, Martin Langer
  • Patent number: 11089046
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: August 10, 2021
    Assignee: KIVU CONSULTING, INC.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 11082443
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: August 3, 2021
    Assignee: KIVU CONSULTING, INC.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Publication number: 20200261542
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: January 24, 2020
    Publication date: August 20, 2020
    Inventors: Britta GÖBEL, Mark SOMMERFELD, Oliver BOSCHEINEN, Thomas LANGER, Christine RUDOLPH, Andreas EVERS
  • Publication number: 20200255540
    Abstract: Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 13, 2020
    Inventors: Christian Beil, Karl-Christian Engel, Gerhard Hessler, Soraya Hoelper, Christian Lange, Thomas Langer, Cendrine Lemoine, Wulf-Dirk Leuschner, Sevim Oezguer Bruederle, Ercole Rao, Nadja Spindler, Sandra Weil
  • Publication number: 20200228562
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 16, 2020
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Publication number: 20200220895
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10609065
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely identifies and maps sensitive information from computers across the enterprise. Secure and sensitive information may be internally encrypted and analyzed for indicators of compromise, threatening behavior, and known vulnerabilities. The remote, agent-less collection, analysis, and identification process can be repeated periodically to detect and map additional sensitive information over time, and may delete itself after completion to avoid detection.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 31, 2020
    Assignee: KIVU CONSULTING, INC.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10594719
    Abstract: Embodiments of the present invention provide techniques, systems, and methods for remote, agent-less enterprise computer threat data collection, malicious threat analysis, and identification and reporting of potential and real threats present on an enterprise computer system. Specifically, embodiments are directed to a system that securely collects system information from computers across the enterprise, internally encrypts and analyzes the collected information for indicators of compromise, threatening behavior, and known vulnerabilities, and generates alerts regarding known and potential threats for further analysis and remediation. If potential threats are identified, the system may deploy a memory analysis module that takes a deeper analysis of the potentially compromised computer to obtain more information about the potential threat.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 17, 2020
    Assignee: Kivu Consulting, Inc.
    Inventors: Elgan David Jones, Thomas Langer, Winston Krone
  • Patent number: 10583174
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 10, 2020
    Assignee: SANOFI
    Inventors: Britta Göbel, Mark Sommerfeld, Oliver Boscheinen, Thomas Langer, Christine Rudolph, Andreas Evers
  • Publication number: 20190100498
    Abstract: The application relates to a crystalline form of the compound of formula (I).
    Type: Application
    Filed: March 24, 2016
    Publication date: April 4, 2019
    Inventors: Thomas LANGER, Paul Allen BETHEL, Mohammed PERVEZ, Lai Chun CHAN, Sophie JANBON
  • Publication number: 20190085043
    Abstract: The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to pharmaceutical compositions, medical uses and methods of treatment involving the fusion protein, particularly in the field of diabetes, dyslipidemia, obesity and/or adipositas.
    Type: Application
    Filed: July 27, 2018
    Publication date: March 21, 2019
    Inventors: Oliver Boscheinen, Matthias Dreyer, Paul Habermann, Hans-Ludwig Schaefer, Mark Sommerfeld, Thomas Langer
  • Publication number: 20180371041
    Abstract: The present invention relates to polypeptide variants of human fibroblast growth factor 21 (FGF21) and fusion molecules thereof, as well as to nucleic acid molecules encoding the same. It further relates to their use as medicaments, in particular for the treatment of obesity, overweight, metabolic syndrome, diabetes mellitus, hyperglycemia, dyslipidemia, non-alcoholic steatohepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 27, 2018
    Inventors: Mark SOMMERFELD, Thomas LANGER, Oliver BOSCHEINEN, Matthias DREYER, Werner DITTRICH, Paul HABERMANN
  • Publication number: 20180236037
    Abstract: The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis.
    Type: Application
    Filed: December 22, 2017
    Publication date: August 23, 2018
    Inventors: Britta GÖBEL, Mark SOMMERFELD, Oliver BOSCHEINEN, Thomas LANGER, Christine RUDOLPH, Andreas EVERS
  • Patent number: 9975881
    Abstract: There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: May 22, 2018
    Assignee: ASTRAZENECA AB
    Inventors: Stephen Connolly, Mark Richard Ebden, Iain Alastair Stewart Walters, Thomas Langer, Alan Robert Steven, Craig Robert Stewart, Paula Margaret Tomlin, Andrew John Williams
  • Publication number: 20180057567
    Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Ercole Rao, Christian Beil, Christian Lange, Katja Kroll, Wulf-Dirk Leuschner, Ingo Focken, Thomas Langer, Nadja Spindler